Zonegran is a new antiepileptic drug - of a new class- with the indication as adjunctive therapy in the treatment of adult patients with partial seizures with or without generalization.
The efficacy is fewer epileptic seizures in a large group of patients with insufficient effect of treatment with one drug only. The efficacy is partly drawn from a reduction in the number of seizures during a period of a maximum 12 weeks, and partly from the quantity of patients, who experience a 50 % reduction in the number of seizures compared to placebo. The Number needed to treat (NNT) - in order to obtain a 50 % reduction in the frequency of seizures - is 6. No other comparable trials with add-on antiepileptic drugs are available.
Adverse events include ataxia, vertigo/dizziness, fatigue, drowsiness, nausea, agitation and reduced appetite, and occur 2-4 times more frequent than treatment with placebo.
The costs are 1½-3 times higher than other new antiepileptic drugs except for Keppra.
Zonegran was marketed March 5, 2006.
Institute for Rational Pharmacotherapy, 23 March 2006